Mon, Apr. 25, 4:12 PM
Fri, Jan. 22, 12:44 PM
Thu, Jan. 21, 4:24 PM
- Vascular Solutions (NASDAQ:VASC): Q4 EPS of $0.33 beats by $0.06.
- Revenue of $38.1M (+13.4% Y/Y) beats by $0.56M.
- Shares +3.4%.
Jul. 22, 2015, 12:45 PM
Jul. 21, 2015, 4:11 PM
- Vascular Solutions (NASDAQ:VASC): Q2 EPS of $0.29 beats by $0.04.
- Revenue of $37.6M (+22.6% Y/Y) beats by $2.01M.
- Shares +1.5%.
Nov. 14, 2014, 12:46 PM
Mar. 27, 2013, 12:42 PM
Investors shrug off what appears to be old news about an FDA recall of Vascular Solutions (VASC +5.3%) Guardian II valve, pushing the stock higher after Piper Jaffray initiated the shares with an Overweight rating and an $18 price target. The company had issued its own recall of the valve earlier this month, citing a slightly increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death.| Mar. 27, 2013, 12:42 PM
Aug. 16, 2012, 3:27 PM
Vascular Solutions (VASC -2%) says that on June 28, it received a subpoena from the U.S. Attorney’s Office in Texas under the Health Insurance Portability & Accountability Act requesting documents related to the company’s Vari-Lase products, particularly related to the use of its Vari-Lase Short Kit for the treatment of perforator veins. The request is related to a recently unsealed complaint filed in 2010 by a former sales employee, alleging kickbacks to physicians for using its product.| Aug. 16, 2012, 3:27 PM